Technology appraisal (TA)	Technology appraisal (TA)  Date of TA  Release  Adherence of local formulary to NICE		
	Release	Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2023-24			
TA879 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)	06/04/2023	No	Terminated appraisal
TA880 - Tezepelumab for treating severe asthma	20/04/2023	No	Not a NICE commissioned site
A881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	03/05/2023	No	Not recommended by NICE
TA882 - Voclosporin with mycophenolate mofetil for treating lupus nephritis	03/05/2023	No	Not a NICE commissioned site
TA883 - Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	03/05/2023	No	Not recommended by NICE
TA884 - Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)	03/05/2023	No	Terminated appraisal
TA885 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	03/05/2023	No	Condition not treated at CWFT
TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2- negative high-risk early breast cancer after chemotherapy	10/05/2023	Yes	
TA887 - Olaparib for previously treated BRCA mutation-positive hormone- relapsed metastatic prostate cancer	10/05/2023	Yes	
TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease	17/05/2023	Yes	
TA889 - Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)	17/05/2023	No	Terminated appraisal
TA890 - Difelikefalin for treating pruritus in people having haemodialysis	17/05/2023	No	Condition not treated at CWFT
TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	31/05/2023	Yes	
TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma	31/05/20223	No	Not recommended by NICE
TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	07/06/2023	No	Condition not treated at CWFT
TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma	07/06/2023	No	Not recommended by NICE
TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	07/06/2023	No	Condition not treated at CWFT
TA896 - Bulevirtide for treating chronic hepatitis D	07/06/2023	No	Not a NICE commissioned site
TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	06/06/2023	Yes	
TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	14/06/2023	Yes	

TA899 - Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)	06/06/2023	No	Terminated appraisal
TA900 - Tixagevimab plus cilgavimab for preventing COVID-19	14/06/2023	No	Not recommended by NICE
TA901 - Cemiplimab for treating recurrent or metastatic cervical cancer	20/06/2023	No	Terminated appraisal
TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	21/06/2023	Yes	
TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	21/06/2023	Yes	
TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	21/06/2023	No	Condition not treated at CWFT
TA905 - Upadacitinib for previously treated moderately to severely active Crohn's disease	21/06/2023	Yes	
TA906 - Rimegepant for preventing migraine	05/07/2023	Yes	
TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis	28/06/2023	Yes	
TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	05/07/2023	No	Condition not treated at CWFT
TA909 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer	12/07/2023	No	Not recommended by NICE
TA910 - Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)	13/07/2023	No	Terminated appraisal
TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small- cell lung cancer	26/07/2023	Yes	
TA912 - Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease	15/08/2023	No	Not a NICE commissioned site
TA913 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy	06/09/2023	No	Not a NICE commissioned site
TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	20/09/2023	Yes	
TA915 - Pegunigalsidase alfa for treating Fabry disease	04/10/2023	No	Not a NICE commissioned site
TA916 - Bimekizumab for treating active psoriatic arthritis	04/10/2023	Yes	
TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	25/10/2023	Yes	

TA918 - Bimekizumab for treating axial spondyloarthritis	11/10/2023	Yes	
TA919 - Rimegepant for treating migraine	18/10/2023	Yes	
TA920 - Tofacitinib for treating active ankylosing spondylitis	18/10/2023	Yes	
TA921 - Ruxolitinib for treating polycythaemia vera	18/10/2023	Yes	
TA922 - Daridorexant for treating long-term insomnia	18/10/2023	Yes	
TA923 - Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)	19/10/2023	No	Terminated appraisal
TA924 - Tirzepatide for treating type 2 diabetes	25/10/2023	Yes	
TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis	25/10/2023	Yes	
TA926 - Baricitinib for treating severe alopecia areata	25/10/2023	No	Not recommended by NICE
TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	17/10/2023	Yes	
TA928 - Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	01/11/2023	No	Not recommended by NICE
TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	01/11/2023	Yes	
TA930 - Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	15/11/2023	No	Not recommended by NICE
TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia	22/11/2023	Yes	
TA932 - Decitabine-cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)	23/11/2023	No	Terminated appraisal
TA933 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)	29/11/2023	No	Terminated appraisal
TA934 - Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms	29/11/2023	No	Condition not treated at CWFT
TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa	06/12/2023	Yes	
TA936 - Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)	30/11/2023	No	Terminated appraisal
		<del></del>	

TA942 - Empartification for treating chronic kidney disease.  20/12/2023  TA943 - Hybrid closed loop systems for managing blood plucose levels in type.  1 disheles  TA944 - Durvalumab with camcitations and cisplaint for treating unresectable.  1 or advanced bliefy tract cancer.  TA945 - Troosulfan with distarible before allocaterist stem cell transplant for process and in month to 17 years with non-malignant diseases (terminated).  20/12/2024  No Condition not treated at CWFT  TA945 - Troosulfan with bevacitamab for maintenance freatment of advanced high-grade optimise overlan fallops tube or primary perioneal cancer.  TA945 - Loneastuvinab testime for treating released or refractory diffuse large B-cell windows and high-grade B-cell windows after 2 or more systemic freatments.  TA945 - Loneastuvinab testime for treating released or refractory diffuse large B-cell windows and high-grade B-cell windows after 2 or more systemic freatments.  TA945 - Loneastuvinab testime for treating chronic graft-versus-host diseases after 2 or more systemic freatments in people 12 years and over.  TA945 - Nivokinab-relating chronic graft-versus-host diseases after 2 or more systemic treatments in people 12 years and over.  TA951 - Olsoanib with abstraterone for untreated hormone-relapsed metastatic melanoms in people 12 years and over.  TA951 - Olsoanib with abstraterone for untreated hormone-relapsed metastatic germine BRCA mutations.		1		
TASSS - Penticulation and accordance of the control	TA937 - Targeted-release budesonide for treating primary IgA nephropathy	20/12/2023	No	Condition not treated at CWFT
TABLE - Characteristic of resistance between terminated approach  TABLE - Transaction with four fronting ADPL embody concilies amorphositis colors  Bookform flooring - Demonstrated approach  TABLE - Equilibration for treating achieving interest and proposed approach  TABLE - Equilibration for treating achieving interest and proposed approach  TABLE - Equilibration for treating chronic interest and accordance  TABLE - Equilibration for treating chronic interest and accordance  TABLE - Equilibration for treating chronic interest and accordance  TABLE - Invalid above two proposed accordance  TABLE - Discording the four four four four four four four four		07/12/2023	No	Terminated appraisal
TAGET - Invasion with function to maintain actions board discose investi in 1002  TAGES - Probability and control for maintain actions board discose investi in 1002  TAGES - Probability for treating ACPH antibody-positive neuronwellis cation  TAGES - Emognificati for treating actions blood discose investi in 1002  TAGES - Probability for treating actions blood discose investi in 1002  TAGES - Probability for treating actions blood discose investi in 1002  TAGES - Transaction with functionable and classification for treating surresentable or advisered blood shows a functionable of treating surresentable or advisered blood shows a functionable of treating surresentable or advisered blood shows and treating stem and treating stem and treating treating action and treating stem and treating action and treating actions a		13/12/2023	No	Condition not treated at CWFT
TASSS - Hubrid closed loop systems for managing blood allucose levels in loop 1 disbetes  TASSS - Hubrid closed loop systems for managing blood allucose levels in loop 1 disbetes  TASSS - Hubrid closed loop systems for managing blood allucose levels in loop 1 disbetes  TASSS - Hubrid closed loop systems for managing blood allucose levels in loop 1 disbetes  TASSS - Thousand with fluctuations and explaint for treating unrescentable, or advanced blint tract cancer  TASSS - Thousand with fluctuations explaint for treating unrescentable, or advanced blint tract cancer  TASSS - Thousand with fluctuations explaint for treating interested at CWFT  TASSS - Thousand to the fluctuation of treating interested for managing the managing blood allucose levels in loop 17ASSS - Thousand to the fluctuation of treating interested at CWFT  TASSS - Thousand to the fluctuation of the company inerformation of advanced bloop of the company inerformation of advanced interested set CWFT  TASSS - Thousand to treating advanced children on the company inerformation on the company in the com		20/12/2023	No	Terminated appraisal
TA943 - Hybrid closed topo systems for managing blood placone levels in type 19412/2023  N/A  Medical device  10012024  No  Condition not treated at CWFT  TA944 - Durvahmab with genicitables and cloplatin for treating unresectable or advanced bilary tract cancer  TA945 - Tricosulfar with dustrables before allocenesis atten cell transplant for people sized 1 month to 17 viers with non-medicant diseases therminated appraisal  TA946 - Clinarib with betweeksumab for maintenance treatment of advanced bish-prade segment of the people sized 1 month to 17 viers with non-medicant diseases therminated appraisal  TA946 - Clinarib with betweeksumab for maintenance treatment of advanced bish-prade segment of the people sized to primary peritorial cancer  TA947 - Loncestourises betweeks for treating religioned or refractory diffuse, large 8-sel k-methoria and shab-grade 8-sel k-methoria and shab	TA941 - Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)	20/12/2023	No	Terminated appraisal
TA944 - Durvalumab with openiciation and cisplatin for treating unresectable or selvenced bilery tract cancer  TA945 - Treasulan with fluderabine before allogeneic stem cell transplant for pascels assed 1 month to 17 years with non-maintenant diseases (terminated, appraisa)  TA946 - Oliparab with bevacizumab for maintenance treatment of advanced inth-practs applied to varian, fatibosin tube or primary perforeal cancer  TA947 - Loneastudinab bisine for treating released or refractory diffuse barce B-cell tymphoma and noth-practs B-cell tymphoma after 2 or more systemic treatments  TA948 - Nosidenic for treating advanced cholenoicoarcinoma with an IOH1. R132 mutation after 1 or more systemic treatments  TA949 - Belamosual for treating advanced cholenoicoarcinoma with an IOH1. R132 mutation after 1 or more systemic treatments  TA949 - Nowidenic for treating advanced cholenoicoarcinoma with an IOH1. R132 mutation after 1 or more systemic treatments.  TA949 - Belamosual for treating chonic cardi-versus-host disease after 2 or more systemic treatments in people 12 years and over.  TA950 - Nivolumab-relations for untreated unresectable or metastatic melanoma in people 12 years and over.  TA951 - Ciliparib with abiraterone for untreated hormone-relapsed metastatic problems with abiraterone for untreated hormone-relapsed metastatic problems with abiraterone for untreated hormone-relapsed metastatic problems after 2 or more systemic freatments.  TA952 - Talazoparib for freating HER2-negative advanced breast cancer with germina BRCA mutations  TA953 - Eucocincione acctoride intravtreal implant for treating chronic diabetic macular cedema.  TA954 - Encocritamab for treating relapsed or refractory diffuse large R-cell ymphoma after 2 or more systemic treatments.	TA942 - Empaqliflozin for treating chronic kidney disease	20/12/2023	Yes	
TA945 - Tracosulan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-mailtonant diseases (terminated appraisal)  TA945 - Olaparib with bevacicumab for maintenance treatment of advanced high-prated epithelial ovarian, foliopian tube or primary peritoneal cancer:  TA947 - Loncasturimab tesirne for treating relapsed or refractory diffuse large B-cell windown and inhib-grade B-cell wi	TA943 - Hybrid closed loop systems for managing blood glucose levels in type  1 diabetes	19/12/2023	N/A	Medical device
Decopie aged 1 month to 17 years with non-malignant diseases (terminated appraisal)  TA946 - Olacarib with bevacizumab for maintenance treatment of advanced high-grade epithelal ovarian, fallopian tube or primary pertoneal cancer this-brade epithelal ovarian, fallopian tube or primary pertoneal cancer this-brade epithelal ovarian, fallopian tube or primary pertoneal cancer this-brade epithelal ovarian, fallopian tube or primary pertoneal cancer this brade epithelal ovarian, fallopian tube or primary pertoneal cancer this brade epithelal ovarian, fallopian to treated at CWFT  TA947 - Loncasturinab tearine for treating elapsed or refractory diffuse large B-cell lymphoma and hob-grade B-cell wriphoma and hob-grade B-cel		10/01/2024	No	Condition not treated at CWFT
high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer  TA947 - Loncastuximab testrine for treating relapsed or refractory diffuse large B-cell tymphoma and high-grade B-cell tymphoma after 2 or more systemic treatments  TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments  TA949 - Belumosudii for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over.  TA950 - Nivolumab - relatinab for untreated unresectable or metastatic melanoma in people 12 years and over.  TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer.  TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations  TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular osdema  TA954 - Epcortlamab for treating relapsed or refractory diffuse large B-cell hymphoma after 2 or more systemic treatments.  Only 1701/2024  Yes  TA954 - Epcortlamab for treating relapsed or refractory diffuse large B-cell hymphoma after 2 or more systemic treatments.	people aged 1 month to 17 years with non-malignant diseases (terminated	30/01/2024	No	Teminated appraisal
Image		17/01/2024	No	Condition not treated at CWFT
R132 mutation after 1 or more systemic treatments  31/01/2024  No Condition not treated at CWF1  TA949 - Belumosudii for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over.  TA950 - Nivolumab—relatimab for untreated unresectable or metastatic melanoma in people 12 years and over.  TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer.  TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations  TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell ymphoma after 2 or more systemic treatments.	large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more	31/01/2024	Yes	
TA950 - Nivolumab-relatimab for untreated unresectable or metastatic melanoma in people 12 years and over.  TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer.  TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations  TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments		31/01/2024	No	Condition not treated at CWFT
TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer.  TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations  TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments		07/02/20224	No	Not a NICE commissioned site
TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations  TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments		07/02/2024	Yes	
TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments		07/02/2024	Yes	
TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments  TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations	21/02/2024	Yes	
lymphoma after 2 or more systemic treatments.  06/03/2024  Yes	TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema	13/03/2024	Yes	
TA955 - Dupilumab for treating moderate to severe prurigo nodularis  13/03/2024  No  Not recommended by NICE		06/03/2024	Yes	
	TA955 - Dupilumab for treating moderate to severe prurigo nodularis	13/03/2024	No	Not recommended by NICE

TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over	11/03/2024	Yes	
TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms	20/03/2024	Yes	
TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over	27/03/2024	Yes	
TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis	27/03/2024	Yes	
TA960 - Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)	27/03/2024	No	Terminated appraisal
TA961 - Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)	28/03/2024	No	Terminated appraisal
TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	28/03/2024	No	Condition not treated at CWFT